Methods
AssigneeAstraZeneca AB, a Swedish corporation
InventorsJohn C. Smith, Rakesh Anand, John E.N. Morten
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstraZeneca AB, a Swedish corporation
InventorsJohn C. Smith, Rakesh Anand, John E.N. Morten
Estimating the term…
This invention relates to polymorphisms in the human pyruvate dehydrogenase complex E2 (PDH E2 or PDC E2) gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the PDH E2 gene, and to the use of PDH E2 polymorphism in the diagnosis and treatment of. diseases in which modulation of pyruvate dehydrogenase activity could be of therapeutic benefit, such as diabetes, asthma, obesity, sepsis and peripheral vascular disease. In particular, the invention is based on the discovery of two single nucleotide polymorphisms (SNPs) in the coding region of the human PDH E2 gene.
A method for the diagnosis of a polymorphism in PDH E2 in a human, which method comprises determining the sequence of the human at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO:
An isolated nucleic acid comprising any one of the following polymorphisms:
An allele specific primer capable of detecting a PDH E2 gene polymorphism at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO:
An allele-specific oligonucleotide probe capable of detecting a PDH E2 gene polymorphism at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO:
A method of treating a human in need of treatment with a PDH drug in which the method comprises:
An allelic variant of the human PDH E2 polypeptide in isolated form having a alanine at position 216 and/or an asparagine at position 349 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 216 and/or position 349.
An antibody specific for an allelic variant of human PDH E2 polypeptide having a alanine at position 216 and/or an asparagine at position 349 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variants at position 216 and /or position 349.
Dependencies are inferred from the claim text.